research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Registered voters: 425,305, valid: 371,189, turnout: 87.3% To honour the exceptionally high percentage of pro-German votes in the district of Oletzko, with 2 votes for Poland compared to 28,625 for Germany, the district town Marggrabowa (i.e. Margrave town) was renamed "Treuburg" (TreueGerman = "loyalty") in 1928, with the district following this example in 1933. In the villages of Lubstynek (Klein Lobenstein), Czerlin (Klein Nappern) and Groszki (Groschken) in the District of Osterode in East Prussia (Ostróda), situated directly at the border, the majority voted for Poland and joined Poland after the plebiscite. Other Polish-majority villages were scarce but would have been more numerous if they had not been surrounded by Mazurian German disposed villages, which made a geographical connection with Poland improbable and so votes for Poland would not be useful. The strategic importance of the Prussian Eastern Railway line Danzig-Warsaw passing through the area of Soldau in the Neidenburg District caused it to be transferred to Poland without a plebiscite; it was renamed Działdowo.[1]
Harper Stern (Myha'la) is a new graduate on Pierpoint’s Cross-Product Sales (CPS) desk and one of the series’ protagonists. Brilliant, ruthless, and intensely ambitious, Harper routinely lies and manipulates to get ahead. Raised in Binghamton, New York by an abusive, domineering mother alongside her twin brother John-Daniel, she never graduated from college after suffering a panic attack during her final exams and conceals this to keep her job. She moves to London to escape her past and gravitates toward Eric Tao as a mentor who validates her drive. In series 1, Harper forges college transcripts for HR, moves into Yasmin’s flat, and forms a close but fragile friendship with her. At work, she is torn between Daria, who insists on professionalism and limits, and Eric, whose aggression mirrors her own ambition; Eric admits he knows she never graduated but protects her. Harper’s early client experiences are damaging: hedge fund manager Nicole Craig sexually assaults her, and she fails to win back major client Felim Bichan, prompting Eric to trap and berate her in a conference room. Daria urges Harper to report Eric, leading to his firing. On RIF day, Harper retracts the complaint in exchange for Eric’s reinstatement and Daria’s dismissal, believing only Eric nurtures her potential. The decision isolates her and fractures her friendship with Yasmin. In series 2, Harper remains estranged from Yasmin, and has had a casual sexual relationship with Robert.
=== Population and ethnicity === According to the 2001 United Kingdom census, the wards of Wilmslow North and Wilmslow South have a combined population of 25,498, of which 13,400 (52.5%) are females and 12,098 (47.5%) are males. In addition, 5,197 (20.4%) are aged 16 and under, while 4,780 (18.8%) are aged 65 and over. Ethnic white groups (British, Irish, other) account for 95.9% of the population, with ethnic minority groups accounting for 4.1% of the population.
Sources: en.wikipedia.org
The reactivity of the reactor after the shutdown first decreases, then increases again, having a shape of a pit; this gave the "iodine pit" its name. The degree of poisoning, and the depth of the pit and the corresponding duration of the outage, depends on the neutron flux before the shutdown. Iodine pit behavior is not observed in reactors with neutron flux density below 5×1016 neutrons m−2s−1, as the 135Xe is primarily removed by decay instead of neutron capture. As the core reactivity reserve is usually limited to 10% of Dk/k, thermal power reactors tend to use neutron flux at most about 5×1013 neutrons m−2s−1 to avoid restart problems after shutdown. The concentration changes of 135Xe in the reactor core after its shutdown is determined by the short-term power history of the reactor (which determines the initial concentrations of 135I and 135Xe), and then by the half-life differences of the isotopes governing the rates of its production and removal; if the activity of 135I is higher than activity of 135Xe, the concentration of 135Xe will rise, and vice versa. During reactor operation at a given power level, a secular equilibrium is established within 40–50 hours, when the production rate of iodine-135, its decay to xenon-135, and its burning to xenon-136 and decay to caesium-135 are keeping the xenon-135 amount in the reactor constant at a given power level. The equilibrium concentration of 135I is proportional to the neutron flux φ. The equilibrium concentration of 135Xe, however, depends very little on neutron flux for φ > 1017 neutrons m−2s−1.
==== As a career choice in the US ==== Psychiatry was not a popular career choice among medical students, even though medical school placements are rated favorably. This has resulted in a significant shortage of psychiatrists in the United States and elsewhere. Strategies to address this shortfall have included the use of short 'taster' placements early in the medical school curriculum and attempts to extend psychiatry services further using telemedicine technologies and other methods. Recently, however, there has been an increase in the number of medical students entering into a psychiatry residency. There are several reasons for this surge, including the intriguing nature of the field, growing interest in genetic biomarkers involved in psychiatric diagnoses, and newer pharmaceuticals on the drug market to treat psychiatric illnesses.
== Background == By the mid-1790s, Humboldt had devoted himself wholly to scientific investigations. Despite being offered a promotion and an increase in pay, he resigned his position as a mining official in the Prussian civil service in order to embark on a journey that would “advance him scientifically.” To the Minister of Mines in Berlin Humboldt declared: "I am considering a complete change in my mode of life, and I intend to withdraw from any official position with the state." His health, he claimed, had suffered. All he had wanted was to prepare himself for a scientific expedition by a practical employment in the mines. "As I have a deep conviction that such an expedition is highly important for increasing our knowledge of geology and physical science, I am exceedingly eager to devote my energies immediately to this end. After his mother's death in 1796, Humboldt inherited the financial means to pursue independent explorations. He decided to go to Italy, where he wanted to spend a year to a year and a half researching volcanoes. From there, he wanted to travel via Paris to England, where he would board a ship to the West Indies. However, the political instability caused by Napoleon's Italian campaign in 1797 forced Humboldt to cancel his plans. In May 1798, Humboldt traveled to Paris, where he met the botanist Aimé Bonpland. After their attempt to travel to Egypt had once again failed due to Napoleon and his campaign there, the two decided to go to Madrid in December 1798.
==== Muscle fibers ==== Typically muscle fibers surround the hydrostatic body. There are two main types of muscle fibers orientations that are responsible for the movement: the circular orientations and longitudinal orientations. Circular muscles decrease the diameter of a hydrostatic body, resulting in an increase in the length of the body, whereas longitudinal muscles shortens the length of a hydrostatic body, resulting in an increase in the diameter of the body. There are four categories of movements of a hydrostatic skeleton: elongation, shortening, bending and torsion. Elongation, which involves an increase in the length of a hydrostatic body requires either circular muscles, a transverse muscle arrangement, or radial muscle arrangement. For a transverse muscle arrangement, parallel sheets of muscle fibers that extend along the length of a hydrostatic body. For a radial muscle arrangement, radial muscles radiate from a central axis along the axis perpendicular to the long axis. Shortening involves the contraction of the longitudinal muscle. Both shortening and bending involve the contraction of longitudinal muscle, but for bending motion some of the antagonistic muscles work synergistically with longitudinal muscles. The amplitude of movements are based upon the antagonistic muscles forces and the amount of leverage the antagonistic muscle provides for movement. For the torsion motion, muscles are arranged in helical layers around a hydrostatic body.
Sources: en.wikipedia.org
==== Netherlands ==== A brand called UGGO is sold in the Netherlands, which offers several different flavors of cream soda. The Surinamese soft drink brand Fernandes, widely available in the country, sells cream soda under the name Green Punch; as the name implies, it is green in color. Asian (especially Chinese) supermarkets also sell Schweppes Cream Soda, which is imported from Hong Kong. A&W is sold in some supermarkets. Old Jamaica Cream Soda (Jamaica) is also sold in the Netherlands.
Tellurocysteine (in some publications referred to as Te-Cys) is an amino acid with the formula HTeCH2CH(NH2)CO2H. It is the heavy analogue of serine, cysteine, and selenocysteine. Tellurol (RTeH) is a rare and fragile functional group, especially alkyl derivatives. The C-Te bond (200 kJ/mol) is weak compared to 234 kJ/mol for the C-Se bond. These factors combine to make tellurocysteine very labile. Even selenocysteine occurs only rarely in nature. Instead of tellurocysteine, tellurocystine is generally isolated instead. Tellurocystine has the formula (TeCH2CH(NH2)CO2H)2, with a central Te-Te bond.
Nucleic acid was, partially, first discovered by Friedrich Miescher in 1869 at the University of Tübingen, Germany. He discovered a new substance, which he called nuclein and which - depending on how his results are interpreted in detail - can be seen in modern terms either as a nucleic acid-histone complex or as the actual nucleic acid. Phoebus Levene determined the basic structure of nucleic acids. In the early 1880s, Albrecht Kossel further purified the nucleid acid substance and discovered its highly acidic properties. He later also identified the nucleobases. In 1889 Richard Altmann created the term nucleic acid – at that time DNA and RNA were not differentiated. In 1938 Astbury and Bell published the first X-ray diffraction pattern of DNA. In 1944 the Avery–MacLeod–McCarty experiment showed that DNA is the carrier of genetic information and in 1953 Watson and Crick proposed the double-helix structure of DNA. Experimental studies of nucleic acids constitute a major part of modern biological and medical research, and form a foundation for genome and forensic science, and the biotechnology and pharmaceutical industries.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.